Despite tremendous advancements in detection and treatment, cancer continues to rank among the world's top causes of morbidity and mortality. Systemic toxicity, drug resistance, and poor tumor selectivity are common limitations of conventional treatments such chemotherapy, radiation, and surgery. Because therapeutic enzymes may catalyze certain biochemical events that impair cancer cell metabolism or accelerate tumor destruction, they have become attractive medicines for targeted cancer therapy in recent decades. L-asparaginase is the most popular and efficient enzyme for treating acute lymphoblastic leukemia (ALL), although other enzymes including collagenase, streptokinase, uricase, and L-asparaginase have also shown clinical and preclinical promise. Their wider use is hampered by issues including immunogenicity, short circulation half-life, and off-target effects. Through novel approaches to nano …